Astellas Venture Management LLC — Full Portfolio

Casma is a biotech company developing technology that uses the autophagy pathway to degrade disease targets for therapeutic applications.

BiotechDeep TechHealthtechBoston, US

ABAndrea Ballabio(Founder)BLBeth Levine(Founder)Herbert Virgin(Founder)JHJames Hurley(Founder)in

Co-investorsTHThird Rock VenturesEIEisai Innovation, Inc.ONOno Venture Investment, Inc.THThe Column Group

Avilar develops ATACs (ASGPR Targeting Chimeras), a class of protein degraders designed to target extracellular and membrane-bound proteins by harnessing the endolysosome's natural degradation process.

BiotechWaltham, US

THERESA CAMERON(Director)MFMARTIN FREED(Director)inSTEPHANIE TOZZO(Executive Officer)PHIL GRAHAM(Executive Officer)MDMILIND DESHPANDE(Director)DAVID NEAFUS(Executive Officer)

Co-investorsMEMedical Excellence CapitalRARA CapitalSASanofi VenturesOPOpenSky Ventures

The page presents Pinco Casino, an online gambling platform offering slots, live casino, table games, and sports betting with a Turkish-language interface.

ConsumerGamingHealthtechBoston, US

Robert Kotin(Executive Officer, Director)Chen Schor(Director)Robert Hadfield(Executive Officer)John Lawrence(Executive Officer)

BoardGVGeeta Vemuri(Director)inDYDerek Yoon(Director)in

Co-investorsDCDC Investment PartnersSOSolasta VenturesUTUTokyo Innovation Platform Co. Ltd.AGAgent CapitalLOLongwood Fund

Catamaran Bio develops allogeneic CAR-NK cell therapies for cancer treatment, focusing on solid tumors, by combining natural killer (NK) cell biology with synthetic biology and non-viral cell engineering.

BiotechHealthtech

BMBranden Moriarity(Scientific Co-founder)Catherine Bollard(Scientific Co-founder)

Co-investorsSOSofinnova PartnersLILightstone Ventures

Cellular Intelligence develops cell therapy treatments, specifically acquiring STEM-PD, a Phase 2-ready therapy for Parkinson's disease.

AI & Machine LearningBiotechMedical Devices

MBMicha Breakstone(CEO & co-founder)inAllon Klein(Scientific Co-founder)inOlivier Pourquié(Scientific Co-founder)inCTCliff Tabin(Scientific Co-founder)inJay Shendure(Scientific Co-founder)in

Co-investorsFUFusionHAHarpoon VenturesLELerer HippeauMAmark vcSCSciFi VCENEntrée Capital+1 more

BiotechBurlingame, US

Mark Rolfe(Executive Officer)LSLaura Shawver(Executive Officer, Director)inTimothy Smith(Executive Officer)

BoardASAlfred Scheidegger(Director)inPTPeter Thompson(Director)inCarol Gallagher(Director)in

Co-investorsNENew Enterprise Associates (NEA)NENextech Invest5A5AM VenturesCLClarus VenturesOROrbiMedOSOsage University Partners+1 more

Crescendo Biologics develops novel immune cell-enhancing therapeutics for immuno-oncology using its patent-protected Humabody VH platform, a fully human domain technology clinically validated in oncology and immunology.

BiotechHealthtechMedical Devices

Co-investorsANAndera PartnersQUQuan CapitalSOSofinnova PartnersEMEMBL VenturesFUFuture Planet CapitalAVAvlar BioVentures+1 more

DEM BioPharma is a biotechnology company developing cancer therapies by targeting the immune system, drawing on genetic and immuno-oncology research.

BiotechHealthtechCambridge, US

NGNenad Grmusa(Chief Executive Officer)inJMJohn McCabe(Chief Financial and Operating Officer)in

Co-investorsALAlta PartnersDCDC Investment PartnersLOLongwood FundPFPfizer Venture InvestmentsUTUTokyo Innovation Platform Co. Ltd.INInsight Partners+1 more

eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company.

BiotechSolana Beach, US

Stephen F. Worland, Ph.D.(Executive Officer, Director)AMAlana McNulty(Executive Officer)in

BoardSimeon George(Director)JRJonathan Root(Director)inKen Haas(Director)Laurence Lasky(Director)

Co-investorsMIMission Bay CapitalMIMission BiocapitalOUOUP (Osage University Partners)PFPfizer Venture InvestmentsUSUS Venture PartnersSOSofinnova Ventures

F2G develops medicines to treat serious fungal diseases where existing therapies have failed or are ineffective.

BiotechDigital HealthHealthtechMedical Devices

Co-investorsADAdvent Life SciencesAIAisling CapitalAMAMR Action FundBRBrace PharmaSOSofinnova PartnersSUSunstone Capital+3 more

Heartseed develops cardiac regenerative medicine, creating heart muscle cells from iPS cells for transplantation to treat heart failure, with its lead pipeline HS-001 nearing clinical trials.

BiotechHealthtechMedical Devices

KFKeiichi Fukuda(代表取締役社長 (President & CEO))

Co-investorsANAngel Bridge Co.,Ltd.KEKeio Innovation InitiativeMEMedical Incubator Japan K.K.SMSMBC Venture CapitalSUSumitomo Mitsui Trust nvestment Co. Ltd.UTUTokyo Innovation Platform Co. Ltd.

LUCA Science develops mitochondrial therapies that supply functional, storable mitochondria to damaged or dysfunctional cells and tissues to restore cellular energy production, targeting conditions such as ischemia-reperfusion injuries including cerebral and myocardial infarction.

BiotechDeep TechHealthtechLongevity

Co-investorsFAFast Track InitiativeRERemiges Ventures, Inc.4B4BIO CapitalDCDCI Partners Co. Ltd.

Mogrify is a biotechnology company developing in vivo cellular reprogramming therapies, using its proprietary MOGRIFY and epiMOGRIFY platforms that apply transcriptomic and epigenetic data to identify transcription factor combinations for converting one cell type into another.

BiotechDeep TechHealthtech

JGJulian Gough(Co-founder)inOROwen Rackham(Co-founder)inJose Polo(Co-founder)inDMDarrin M. Disley(CEO)in

BoardJane Osbourn(Chair)

Co-investorsAHAhren Innovation CapitalPAParkwalk Advisors

Neophore develops a small-molecule therapeutic that transiently inhibits DNA Mismatch Repair (MMR) to convert MMR-proficient tumours into an MMR-deficient state, making them responsive to cancer immunotherapy.

AI & Machine LearningBiotechLongevity

Co-investors3B3B Future Health FundCLClaris VenturesNENeva Sgr.

Cambridge, US

CQChristophe Queva(Executive Officer)inTheodore Ashburn(Executive Officer, Director)Alon Lazarus(Director)Cameron Wheeler(Director)in

BoardBMBriggs Morrison(Director)inMitchell Finer(Executive Officer, Director)

Co-investorsCOCowen Healthcare InvestmentsDEDeerfield Management CompanyK2K2 HealthVenturesMPMPM BioImpact

Orna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications.

AI & Machine LearningBiotechMedical Devices

JBJoe Bolen(Chief Executive Officer)JBJoe Bolen, Ph.D.(Chief Executive Officer)Hope D'Oyley-Gay, JD(Chief Legal Officer)CLCiaran Lawlor, Ph.D.(Chief Operating Officer)FNFrank Neumann, M.D., Ph.D.(Chief Medical Officer)SSSiva Sakhamuri(Chief Technology Officer)in

Co-investorsMPMPM BioImpactTATaiho Ventures, LLC

Palland Tx is developing next-generation targeted protein degraders aimed at improving therapeutic efficacy through precision targeting.

Biotech

BiotechMt. Arlington, US

Paul Chaney(Executive Officer, Director)

BoardACAbbie Celniker(Director)inDavid Guyer(Director)Bruce Peacock(Director)Kevin Starr(Director)inLutz Giebel(Director)

Co-investorsAGAgent CapitalSVSV Health InvestorsTHThird Rock Ventures

PhoreMost is a biotechnology company developing small molecule drugs and targeted protein degradation therapeutics for cancers with high unmet clinical need, with a lead program (PMC-001) for primary and metastatic brain cancers in Phase 1/2a clinical evaluation.

BiotechMedical DevicesCambridge, GB

Co-investorsAMAmadeus Capital PartnersCACambridge Angels groupUNUniversity of Cambridge EnterpriseAMAmadeus Capital SAO2O2h VenturesPAParkwalk Advisors

Redona Therapeutics is a drug discovery company co-founded by Harvard Medical School investigators focused on novel areas of biology.

AI & Machine LearningBiotechBoston, US

George Daley(Co-founder)Richard Gregory(Co-founder)Frank Slack(Co-founder)Piotr Sliz(Co-founder)inKSKazumi Shiosaki(President & CEO)in

Co-investorsOUOUP (Osage University Partners)SOSofinnova Partners

ResNovas Therapeutics appears to be a therapeutics company, but the page provides no usable details about its products, technology, or market.

Biotech

Restore Vis is a life sciences company founded by a vitreoretinal surgeon and clinician scientist focused on addressing inflammation, aging, neurodegeneration and angiogenesis through translational research from drug discovery to clinical trials.

BiotechDigital HealthHealthtechMedical DevicesTokyo, JP

Dr. Rajendra S. Apte(Paul A. Cibis Distinguished Professor; Vice Chair of Innovation and Translation; Founder)Yusaku Katada MD, PhD(Co-founder, Representative Director and CEO/CMO)HMHikaru Miyazaki(Representative Director and COO)in

Co-investorsDBDBJ CapitalJIJIC Venture Growth InvestmentsKYKyoto University Innovation CapitalNINippon Venture CapitalOSOSAKA University Venture CapitalRERemiges Ventures, Inc.+3 more

Shinobi develops next-generation cell therapies using iPSC (induced pluripotent stem cell) research, genetic engineering, and clinical infrastructure.

AI & Machine LearningBiotechHealthtechMedical Devices

Co-investorsF-F-Prime CapitalFAFast Track InitiativeJIJIC Venture Growth InvestmentsKYKyoto University Innovation CapitalEQEQT Life Sciences

Sidewinder Therapeutics is a biotechnology company focused on oncology drug discovery and development, working on next-generation cancer treatments.

BiotechHealthtechMedical DevicesSan Diego, US

EMEric Murphy(Chief Executive Officer, Co-Founder, & Director)in

Co-investorsDCDCVC (Data Collective)DCDCVC BioFRFrazier Life SciencesLOLongwood FundNONovartis Venture FundOROrbiMed+2 more

Solu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels.

BiotechHealthtech

PVPhil Vickers(CEO / Leadership)inMBMichael Boretti(Leadership)inBTBrandon Turunen(Leadership)inSSSergio Santillana(Leadership)EMEnda Moran(Leadership)inKHKelly Honohan(Leadership)in

Co-investorsLOLongwood FundPAPappas Capital

Syntax Bio develops a discovery platform that accelerates stem cell-derived therapies by using its proprietary Cellgorithm technology to control and direct cell differentiation.

BiotechDeep TechMedical DevicesChicago, US

Ryan Clarke(Co-Founder, Chief Scientific Officer)inNBNiko Balanis, PhD(Co-Founder, Chief Technology Officer)inBrad Merrill, PhD(Co-Founder, Head of Innovation)MMMatt MacDougall, MD, PhD(Scientific Cofounder, Immunology Physician, Stanford University)inPatrick Shaddow(Executive Officer, Director)John Craighead, PhD(Chief Executive Officer)

Co-investorsDCDCVC (Data Collective)DCDCVC BioDRDraper AssociatesILIllumina VenturesPOPortal InnovationsWAWalder Ventures

Tizona Therapeutics is a biotechnology company developing first-in-class immuno-oncology therapeutics, including its lead clinical-stage asset TTX-080, aimed at changing cancer progression and relapse.

AI & Machine LearningBiotechHealthtech

VKVijay K. Kuchroo(Scientific Co-Founder & Advisory Board Member)Drew Pardoll(Scientific Co-Founder & Advisory Board Member)Dario Vignali(Scientific Co-Founder & Advisory Board Member)Jedd Wolchok(Scientific Co-Founder & Advisory Board Member)COChristine O'Brien(Chief Executive Officer & Board Member)inCBCourtney Beers(Chief Scientific Officer)

Co-investorsCACanaan PartnersMPMPM BioImpactABAbingworthGIGilead SciencesLILightstone Ventures

Trishula Therapeutics is a clinical-stage biopharmaceutical company developing TTX-030, a first-in-class anti-CD39 antibody for advanced cancers.

BiotechHealthtech

ASAnil Singhal(President and CEO)inSMSiddhartha Mitra(Chief Medical Officer)in

Co-investorsCACanaan PartnersMPMPM BioImpactLILightstone Ventures

A company focused on developing clinical treatments aimed at improving patient outcomes.

BiotechHealthtechMedical DevicesBoston, US

DSDavid Southwell(Executive Officer, Director)inRobert Crane(Executive Officer)

BoardLHLea Hachigian(Director)SKSteve Kraus(Director)inCMCampbell Murray(Director)inHSHannes Smarason(Director)in

Co-investorsBEBessemer Venture PartnersLOLongwood FundRARA Capital6 6 Dimensions CapitalLOLongwood Special SituationsPIPitango

Viamet provides a resource for people to organize questions and conduct research about medical travel, provider verification, care coordination, and health-related travel planning.

Digital HealthHealthtechTravel & HospitalityWellness & Fitness

Co-investorsHAHatteras Venture PartnersLILilly VenturesNONovartis Venture FundWOWoodford Investment Management

Toregem Biopharma is a Kyoto University spin-off developing a tooth-regeneration drug based on a humanized anti-USAG-1 antibody that aims to regrow teeth with a single injection.

BiotechDeep TechHealthtechMedical Devices京都 (Kyoto), JP

喜早 ほのか (Honoka Kihayashi)(代表取締役社長 (Representative Director and President))髙橋 克 (Katsu Takahashi)(取締役CTO (Director and CTO))髙谷 宗男 (Muneo Takaya)(取締役CBO (Director and CBO))喜ほ喜早 ほのか(Co-founder & CEO (代表取締役社長))髙克髙橋 克(Co-founder & CTO)髙宗髙谷 宗男(Co-founder & CBO)

Co-investorsKYKyoto University Innovation Capital